> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncologic Panel to Review Lung Cancer Therapy
- URL: https://www.fdaweb.com/oncologic-panel-to-review-lung-cancer-therapy/
- Published: 2021-12-14T12:00:00.000Z
- Updated: 2026-09-14T17:25:45.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150761

*Federal Register* notice: FDA has announced a 2/10/2022 Oncologic Drugs Advisory Committee meeting. Panel members are scheduled to discuss and vote on an Innovent Biologics BLA for sintilimab for injection, indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with Stage IIIB, IIIC, or Stage IV non-squamous non-small cell lung cancer with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-12-13/pdf/2021-26891.pdf?ref=fdaweb.com).